4216 RESULTS
COMMENT Though we have made substantial progress in characterizing the behavior of biochemical and imaging biomarkers in presymptomatic and manifest Alzheimer’s disease, we still need an inexpensive and noninvasive index for the presence of AD pathology and its ...
COMMENT This study involved persons with dominantly inherited Alzheimer disease mutations who donated plasma samples. The key finding was that ptau181 levels were elevated in both symptomatic and asymptomatic individuals and, in particular, modeling indicated ...
COMMENT This paper provides further evidence that plasma ptau181 may be an excellent blood-based biomarker for Alzheimer disease brain pathology and symptomatic status. Interestingly, the investigators found very high intra-individual variation in p-tau181 levels ...
COMMENT The paper describes changes in plasma concentrations of P-tau181 in familial Alzheimer’s disease. The authors found that similar to plasma NfL, the P-tau181 concentrations started to increase around 15 years prior to symptom onset. The unadjusted ...
COMMENT In this study of P-tau181 and NfL in plasma of familial Alzheimer’s disease, O’Connor et al. leverage an in-house-developed P-tau181 assay and commercial Quanterix NF-Light assay. This NfL assay is widely used. The P-tau181 assay, although new, is gaining ...
Eli Lilly
PAPER Zhou L, Huang JY, Zhang D, Zhao YL
PAPER Iakovenko EV, Abramycheva NY, Fedotova EY, Illarioshkin SN
PAPER Dong W, Ma Y, Guan F, Zhang X, Chen W, Zhang L, Zhang L
PAPER Kimura S, Kamatari YO, Kuwahara Y, Hara H, Yamato O, Maeda S, Kamishina H, Honda R
PAPER Chan YL, Ung WC, Lim LG, Lu CK, Kiguchi M, Tang TB
PAPER Kulkarni P, Grant S, Morrison TR, Cai X, Iriah S, Kristal BS, Honeycutt J, Brenhouse H, Hartner JC, Madularu D, Ferris CF
PAPER Firdaus Z, Singh TD
PAPER Youn K, Jun M
